Merrimack is developing a companion diagnostic for seribantumab to measure the levels of five proteins involved in the ErbB pathway and predicts the activated state of ErbB3 for the diagnosis of cancer (Filing 10-K , Merrimack, MAR 30, 2012, View Source [SID:1234501371]).
Merrimack is developing a companion diagnostics for use of MM-111, to identify overexpression levels of ErbB2 (HER2), ErbB3 and heregulin levels for the diagnosis of cancer
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!